All‐oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment‐naïve patients with genotype 1 HCV infection
This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non‐nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment‐naïve patients with chronic hepatiti...
Saved in:
| Published in | Hepatology (Baltimore, Md.) Vol. 60; no. 1; pp. 56 - 64 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wolters Kluwer Health, Inc
01.07.2014
Wiley-Blackwell |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0270-9139 1527-3350 1527-3350 |
| DOI | 10.1002/hep.27053 |
Cover
| Abstract | This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non‐nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment‐naïve patients with chronic hepatitis C virus (HCV) genotype 1 without cirrhosis. Patients were randomized 1:2 to LDV 30 mg once daily (QD; Arm 1; n = 46) or LDV 90 mg QD (Arm 2; n = 94); patients in both arms also received VDV 200 mg QD, TGV 30 mg twice‐daily, and RBV 1,000‐1,200 mg/day. Patients in Arm 2 with vRVR, defined as HCV RNA below the lower limit of quantification (LLOQ) from treatment weeks 2 to 10, were randomized 1:1 to stop treatment at 12 weeks or continue for 24 weeks. Sustained virologic response 12 weeks after treatment (SVR12) was higher in patients receiving 90 mg of LDV for 24 weeks (63%), compared with LDV 90 mg for 12 weeks (54%) and LDV 30 mg for 24 weeks (48%). In patients with very rapid virologic response (vRVR) in Arm 2, SVR12 was achieved by 68% and 81% of patients treated for 12 and 24 weeks, respectively. Virologic breakthrough was more common in patients with HCV genotype 1a and was associated with resistance‐associated variants for all three direct‐acting antiviral agents (DAAs); however, in all but 1 patient who relapsed, resistance‐associated variants directed against only one or two of the DAAs were detected. The most common adverse events were fatigue, headache, nausea, rash, and diarrhea. Conclusion: In patients with HCV genotype 1, an interferon‐free regimen containing LDV/VDV/TGV/RBV was well tolerated and led to SVR12 in up to 63% of patients. LDV 90 mg is currently being investigated in combination with the nucleotide polymerase inhibitor, sofosbuvir. (Hepatology 2014;60:56–64) |
|---|---|
| AbstractList | This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non-nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 without cirrhosis. Patients were randomized 1:2 to LDV 30 mg once daily (QD; Arm 1; n = 46) or LDV 90 mg QD (Arm 2; n = 94); patients in both arms also received VDV 200 mg QD, TGV 30 mg twice-daily, and RBV 1,000-1,200 mg/day. Patients in Arm 2 with vRVR, defined as HCV RNA below the lower limit of quantification (LLOQ) from treatment weeks 2 to 10, were randomized 1:1 to stop treatment at 12 weeks or continue for 24 weeks. Sustained virologic response 12 weeks after treatment (SVR12) was higher in patients receiving 90 mg of LDV for 24 weeks (63%), compared with LDV 90 mg for 12 weeks (54%) and LDV 30 mg for 24 weeks (48%). In patients with very rapid virologic response (vRVR) in Arm 2, SVR12 was achieved by 68% and 81% of patients treated for 12 and 24 weeks, respectively. Virologic breakthrough was more common in patients with HCV genotype 1a and was associated with resistance-associated variants for all three direct-acting antiviral agents (DAAs); however, in all but 1 patient who relapsed, resistance-associated variants directed against only one or two of the DAAs were detected. The most common adverse events were fatigue, headache, nausea, rash, and diarrhea. CONCLUSION: In patients with HCV genotype 1, an interferon-free regimen containing LDV/VDV/TGV/RBV was well tolerated and led to SVR12 in up to 63% of patients. LDV 90 mg is currently being investigated in combination with the nucleotide polymerase inhibitor, sofosbuvir. This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non-nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 1 without cirrhosis. Patients were randomized 1:2 to LDV 30 mg once daily (QD; Arm 1; n=46) or LDV 90 mg QD (Arm 2; n=94); patients in both arms also received VDV 200 mg QD, TGV 30 mg twice-daily, and RBV 1,000-1,200 mg/day. Patients in Arm 2 with vRVR, defined as HCV RNA below the lower limit of quantification (LLOQ) from treatment weeks 2 to 10, were randomized 1:1 to stop treatment at 12 weeks or continue for 24 weeks. Sustained virologic response 12 weeks after treatment (SVR12) was higher in patients receiving 90 mg of LDV for 24 weeks (63%), compared with LDV 90 mg for 12 weeks (54%) and LDV 30 mg for 24 weeks (48%). In patients with very rapid virologic response (vRVR) in Arm 2, SVR12 was achieved by 68% and 81% of patients treated for 12 and 24 weeks, respectively. Virologic breakthrough was more common in patients with HCV genotype 1a and was associated with resistance-associated variants for all three direct-acting antiviral agents (DAAs); however, in all but 1 patient who relapsed, resistance-associated variants directed against only one or two of the DAAs were detected. The most common adverse events were fatigue, headache, nausea, rash, and diarrhea. Conclusion: In patients with HCV genotype 1, an interferon-free regimen containing LDV/VDV/TGV/RBV was well tolerated and led to SVR12 in up to 63% of patients. LDV 90 mg is currently being investigated in combination with the nucleotide polymerase inhibitor, sofosbuvir. (Hepatology 2014;60:56-64) [PUBLICATION ABSTRACT] This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non‐nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment‐naïve patients with chronic hepatitis C virus (HCV) genotype 1 without cirrhosis. Patients were randomized 1:2 to LDV 30 mg once daily (QD; Arm 1; n = 46) or LDV 90 mg QD (Arm 2; n = 94); patients in both arms also received VDV 200 mg QD, TGV 30 mg twice‐daily, and RBV 1,000‐1,200 mg/day. Patients in Arm 2 with vRVR, defined as HCV RNA below the lower limit of quantification (LLOQ) from treatment weeks 2 to 10, were randomized 1:1 to stop treatment at 12 weeks or continue for 24 weeks. Sustained virologic response 12 weeks after treatment (SVR12) was higher in patients receiving 90 mg of LDV for 24 weeks (63%), compared with LDV 90 mg for 12 weeks (54%) and LDV 30 mg for 24 weeks (48%). In patients with very rapid virologic response (vRVR) in Arm 2, SVR12 was achieved by 68% and 81% of patients treated for 12 and 24 weeks, respectively. Virologic breakthrough was more common in patients with HCV genotype 1a and was associated with resistance‐associated variants for all three direct‐acting antiviral agents (DAAs); however, in all but 1 patient who relapsed, resistance‐associated variants directed against only one or two of the DAAs were detected. The most common adverse events were fatigue, headache, nausea, rash, and diarrhea. Conclusion: In patients with HCV genotype 1, an interferon‐free regimen containing LDV/VDV/TGV/RBV was well tolerated and led to SVR12 in up to 63% of patients. LDV 90 mg is currently being investigated in combination with the nucleotide polymerase inhibitor, sofosbuvir. (Hepatology 2014;60:56–64) This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non-nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 1 without cirrhosis. Patients were randomized 1:2 to LDV 30 mg once daily (QD; Arm 1; n = 46) or LDV 90 mg QD (Arm 2; n = 94); patients in both arms also received VDV 200 mg QD, TGV 30 mg twice-daily, and RBV 1,000-1,200 mg/day. Patients in Arm 2 with vRVR, defined as HCV RNA below the lower limit of quantification (LLOQ) from treatment weeks 2 to 10, were randomized 1:1 to stop treatment at 12 weeks or continue for 24 weeks. Sustained virologic response 12 weeks after treatment (SVR12) was higher in patients receiving 90 mg of LDV for 24 weeks (63%), compared with LDV 90 mg for 12 weeks (54%) and LDV 30 mg for 24 weeks (48%). In patients with very rapid virologic response (vRVR) in Arm 2, SVR12 was achieved by 68% and 81% of patients treated for 12 and 24 weeks, respectively. Virologic breakthrough was more common in patients with HCV genotype 1a and was associated with resistance-associated variants for all three direct-acting antiviral agents (DAAs); however, in all but 1 patient who relapsed, resistance-associated variants directed against only one or two of the DAAs were detected. The most common adverse events were fatigue, headache, nausea, rash, and diarrhea.UNLABELLEDThis phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non-nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 1 without cirrhosis. Patients were randomized 1:2 to LDV 30 mg once daily (QD; Arm 1; n = 46) or LDV 90 mg QD (Arm 2; n = 94); patients in both arms also received VDV 200 mg QD, TGV 30 mg twice-daily, and RBV 1,000-1,200 mg/day. Patients in Arm 2 with vRVR, defined as HCV RNA below the lower limit of quantification (LLOQ) from treatment weeks 2 to 10, were randomized 1:1 to stop treatment at 12 weeks or continue for 24 weeks. Sustained virologic response 12 weeks after treatment (SVR12) was higher in patients receiving 90 mg of LDV for 24 weeks (63%), compared with LDV 90 mg for 12 weeks (54%) and LDV 30 mg for 24 weeks (48%). In patients with very rapid virologic response (vRVR) in Arm 2, SVR12 was achieved by 68% and 81% of patients treated for 12 and 24 weeks, respectively. Virologic breakthrough was more common in patients with HCV genotype 1a and was associated with resistance-associated variants for all three direct-acting antiviral agents (DAAs); however, in all but 1 patient who relapsed, resistance-associated variants directed against only one or two of the DAAs were detected. The most common adverse events were fatigue, headache, nausea, rash, and diarrhea.In patients with HCV genotype 1, an interferon-free regimen containing LDV/VDV/TGV/RBV was well tolerated and led to SVR12 in up to 63% of patients. LDV 90 mg is currently being investigated in combination with the nucleotide polymerase inhibitor, sofosbuvir.CONCLUSIONIn patients with HCV genotype 1, an interferon-free regimen containing LDV/VDV/TGV/RBV was well tolerated and led to SVR12 in up to 63% of patients. LDV 90 mg is currently being investigated in combination with the nucleotide polymerase inhibitor, sofosbuvir. This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non-nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 1 without cirrhosis. Patients were randomized 1:2 to LDV 30 mg once daily (QD; Arm 1; n = 46) or LDV 90 mg QD (Arm 2; n = 94); patients in both arms also received VDV 200 mg QD, TGV 30 mg twice-daily, and RBV 1,000-1,200 mg/day. Patients in Arm 2 with vRVR, defined as HCV RNA below the lower limit of quantification (LLOQ) from treatment weeks 2 to 10, were randomized 1:1 to stop treatment at 12 weeks or continue for 24 weeks. Sustained virologic response 12 weeks after treatment (SVR12) was higher in patients receiving 90 mg of LDV for 24 weeks (63%), compared with LDV 90 mg for 12 weeks (54%) and LDV 30 mg for 24 weeks (48%). In patients with very rapid virologic response (vRVR) in Arm 2, SVR12 was achieved by 68% and 81% of patients treated for 12 and 24 weeks, respectively. Virologic breakthrough was more common in patients with HCV genotype 1a and was associated with resistance-associated variants for all three direct-acting antiviral agents (DAAs); however, in all but 1 patient who relapsed, resistance-associated variants directed against only one or two of the DAAs were detected. The most common adverse events were fatigue, headache, nausea, rash, and diarrhea. In patients with HCV genotype 1, an interferon-free regimen containing LDV/VDV/TGV/RBV was well tolerated and led to SVR12 in up to 63% of patients. LDV 90 mg is currently being investigated in combination with the nucleotide polymerase inhibitor, sofosbuvir. |
| Author | Kanwar, Bittoo Habersetzer, François Mo, Hongmei Herring, Robert W. Zhu, Yanni Rodriguez‐Torres, Maribel Shiffman, Mitchell L. Pol, Stanislas Subramanian, G. Mani Wyles, David L. Trenkle, James D. Massetto, Benedetta Brainard, Diana M. Lawitz, Eric Sulkowski, Mark S. Pang, Phil S. McHutchison, John G. |
| Author_xml | – sequence: 1 givenname: David L. surname: Wyles fullname: Wyles, David L. organization: University of California – sequence: 2 givenname: Maribel surname: Rodriguez‐Torres fullname: Rodriguez‐Torres, Maribel organization: Fundación de Investigación de Diego – sequence: 3 givenname: Eric surname: Lawitz fullname: Lawitz, Eric organization: Texas Liver Institute – sequence: 4 givenname: Mitchell L. surname: Shiffman fullname: Shiffman, Mitchell L. organization: Liver Institute of Virginia – sequence: 5 givenname: Stanislas surname: Pol fullname: Pol, Stanislas organization: Hôpital Cochin – sequence: 6 givenname: Robert W. surname: Herring fullname: Herring, Robert W. organization: Quality Medical Research, PLLC – sequence: 7 givenname: Benedetta surname: Massetto fullname: Massetto, Benedetta organization: Gilead Sciences, Inc – sequence: 8 givenname: Bittoo surname: Kanwar fullname: Kanwar, Bittoo organization: Gilead Sciences, Inc – sequence: 9 givenname: James D. surname: Trenkle fullname: Trenkle, James D. organization: Gilead Sciences, Inc – sequence: 10 givenname: Phil S. surname: Pang fullname: Pang, Phil S. organization: Gilead Sciences, Inc – sequence: 11 givenname: Yanni surname: Zhu fullname: Zhu, Yanni organization: Gilead Sciences, Inc – sequence: 12 givenname: Hongmei surname: Mo fullname: Mo, Hongmei organization: Gilead Sciences, Inc – sequence: 13 givenname: Diana M. surname: Brainard fullname: Brainard, Diana M. organization: Gilead Sciences, Inc – sequence: 14 givenname: G. Mani surname: Subramanian fullname: Subramanian, G. Mani organization: Gilead Sciences, Inc – sequence: 15 givenname: John G. surname: McHutchison fullname: McHutchison, John G. organization: Gilead Sciences, Inc – sequence: 16 givenname: François surname: Habersetzer fullname: Habersetzer, François organization: Inserm 1110, Université de Strasbourg, Hôpitaux Universitaires de Strasbourg – sequence: 17 givenname: Mark S. surname: Sulkowski fullname: Sulkowski, Mark S. organization: Johns Hopkins University School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24501005$$D View this record in MEDLINE/PubMed https://hal.science/hal-02492435$$DView record in HAL |
| BookMark | eNp9kc1uEzEQxy1URNPCgRdAlri0iG39tZv1MYoKQYoEB-C68npnG1dee_F6E-XGkWPfhIfgTXgSnKRQqRKVLHlm9Jv_fJ2gI-cdIPSSkgtKCLtcQX_BpiTnT9CE5myacZ6TIzQhKZhJyuUxOhmGG0KIFKx8ho6ZyEnKzCfox8za399vfVAWa9_VxqlovMO-xRYa06thbcJbvIYm-D7A3olw7etxbyrX4GBqlRzjcHoxgIoduJhEnfr1cw24T4opMOCNiSt8Dc7HbQ-Y4sX8a0ppQe8qPkdPW2UHeHH3n6Iv764-zxfZ8uP7D_PZMtNCMp5xwoRoZEl0zqjUoEhRsrzUlCgl87ot-BQKKKFktBDFlJWCCkolkVqTZEp-it4cdEfXq-1GWVv1wXQqbCtKqt06q7TOar_OBJ8f4JW6x7wy1WK2rHax1I1kgudrmtizA9sH_22EIVadGTRYqxz4cahoLhghXE5FQl8_QG_8GFwae0cRUZSiZIl6dUeNdQfNv_p_j3ffnQ5-GAK0j05y-YDVJu5PHYMy9rGMjbGw_b90tbj6dMj4A2-vyM4 |
| CODEN | HPTLD9 |
| CitedBy_id | crossref_primary_10_1007_s15010_017_1093_1 crossref_primary_10_1136_annrheumdis_2014_206180 crossref_primary_10_1517_14656566_2015_1019862 crossref_primary_10_1515_jtim_2017_0007 crossref_primary_10_1016_j_bmcl_2019_03_037 crossref_primary_10_1189_jlb_5A1116_456R crossref_primary_10_1186_1471_2334_14_503 crossref_primary_10_1097_CRD_0000000000000031 crossref_primary_10_1517_14656566_2015_1013938 crossref_primary_10_2174_1871526519666190121114003 crossref_primary_10_1016_j_antiviral_2017_02_014 crossref_primary_10_1586_17474124_2015_1111757 crossref_primary_10_1053_j_gastro_2016_05_021 crossref_primary_10_1111_jvh_12783 crossref_primary_10_1016_j_coph_2014_07_016 crossref_primary_10_1016_j_antiviral_2017_09_001 crossref_primary_10_1177_1060028014563952 crossref_primary_10_3748_wjg_v22_i29_6573 crossref_primary_10_1038_nrdp_2017_6 crossref_primary_10_1310_hpj5003_224 crossref_primary_10_1016_j_ijantimicag_2015_12_008 crossref_primary_10_1128_JCM_02093_14 crossref_primary_10_1016_j_jhep_2015_09_011 crossref_primary_10_3390_v12050525 crossref_primary_10_1007_s40261_017_0565_5 crossref_primary_10_1002_hep_27836 crossref_primary_10_1007_s40261_017_0521_4 crossref_primary_10_1111_jcpt_12426 crossref_primary_10_1111_jvh_12536 crossref_primary_10_1007_s40262_016_0397_0 crossref_primary_10_1097_MD_0000000000003719 crossref_primary_10_1586_17512433_2016_1129272 crossref_primary_10_1002_rmv_1842 crossref_primary_10_1016_j_jviromet_2017_10_005 crossref_primary_10_4254_wjh_v9_i33_1239 crossref_primary_10_1128_AAC_04227_14 crossref_primary_10_3851_IMP3181 crossref_primary_10_3389_fgene_2020_575012 |
| Cites_doi | 10.1038/nri3463 10.1016/S0168-8278(11)61234-8 10.1056/NEJMoa1012912 10.1053/j.gastro.2013.02.039 10.1056/NEJMoa1208809 10.1111/j.1478-3231.2009.02156.x 10.1053/j.gastro.2011.08.051 10.1056/NEJMoa1104430 10.1016/j.jhep.2011.12.029 10.1056/NEJMoa1010494 10.1016/j.cgh.2013.03.032 |
| ContentType | Journal Article |
| Copyright | 2014 by the American Association for the Study of Liver Diseases 2014 by the American Association for the Study of Liver Diseases. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2014 by the American Association for the Study of Liver Diseases – notice: 2014 by the American Association for the Study of Liver Diseases. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 1XC ADTOC UNPAY |
| DOI | 10.1002/hep.27053 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Hyper Article en Ligne (HAL) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3350 |
| EndPage | 64 |
| ExternalDocumentID | 10.1002/hep.27053 oai:HAL:hal-02492435v1 3349667401 24501005 10_1002_hep_27053 HEP27053 |
| Genre | article Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: NIDA NIH HHS grantid: K24 DA034621 |
| GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX ABJNI ACZKN ADSXY AEFGJ AFNMH AGQPQ AGXDD AHQVU AIDQK AIDYY AIQQE CITATION MEWTI WXSBR CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 1XC ADTOC UNPAY |
| ID | FETCH-LOGICAL-c4923-30244d980c5219cea068258c10aa95bf637e6e8e82164672841411909cc041493 |
| IEDL.DBID | UNPAY |
| ISSN | 0270-9139 1527-3350 |
| IngestDate | Tue Aug 19 22:44:11 EDT 2025 Tue Oct 14 20:29:36 EDT 2025 Wed Oct 01 14:08:05 EDT 2025 Tue Oct 07 05:59:09 EDT 2025 Mon Jul 21 06:03:30 EDT 2025 Wed Oct 01 04:13:10 EDT 2025 Thu Apr 24 23:09:58 EDT 2025 Wed Jan 22 16:48:00 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | http://doi.wiley.com/10.1002/tdm_license_1.1 2014 by the American Association for the Study of Liver Diseases. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4923-30244d980c5219cea068258c10aa95bf637e6e8e82164672841411909cc041493 |
| Notes | Potential conflict of interest: Dr. Herring received grants from Gilead. Dr. Pol consults for and received grants and lecture fees from Bristol‐Myers Squibb, Gilead, Roche, and MSD. He consults for and received lecture fees from Boehringer Ingelheim, Tibotec, Vertex, Novartis, Abbott/AbbVie, Sanofi, and GlaxoSmithKline. Dr. Rodriguez‐Torres consults for and received grants from Akros, Bristol‐Myers Squibb, Genentech, Hoffman‐La Roche, Inhibitex, Merck, Pharmasset, Santaris, and Vertex. She consults for Janssen. She received grants from Abbott, Anadys, Beckman, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Human Genome Sciences, Idenix, Idera, Johnson & Johnson, Mochida, Novartis, Pfizer, Scynexis, Siemens, and Zymogenetics. Dr. Pang owns stock in and is employed by Gilead. Dr. McHutchison owns stock in and is employed by Gilead. Dr. Brainard owns stock in and is employed by Gilead. Dr. Trenkle owns stock in and is employed by Gilead. Dr. Subramanian owns stock in and is employed by Gilead. Dr. Massetto owns stock in and is employed by Gilead. Dr. Mo is employed by Gilead. Dr. Shiffman advises, is on the speakers' bureau for, and received grants from Gilead, Merck, and Roche/Genentech. He advises, consults for, and is on the speakers' bureau for Janssen. He advises and received grants from Achillion, Bristol‐Myers Squibb, Boehringer Ingelheim, Globeimmune, and Novartis. He advises and is on the speakers' bureau for Bayer, Salix, and Vertex. He advises and consults for Gen‐Probe and GlaxoSmithKline. He received grants from AbbVie, Beckman‐Colter, Idenix, Intercept, Lumena, and Mochida. Dr. Lawitz advises, is on the speakers' bureau for, and received grants from Merck and Vertex. He is on the speakers' bureau for and received grants from Gilead and GlaxoSmithKline. He advises and received grants from AbbVie, Achillion, Idenix, Janssen, Novartis, and Santaris. He advises BioCryst, Biotica, Enanta, and Theravance. He is on the speakers' bureau for Kadmon. He received grants from Boehringer Ingelheim, Bristol‐Myers Squibb, Intercept, Medtronic, Presidio, and Roche. Dr. Wyles consults for and received grants from Gilead, AbbVie, and Bristol‐Myers Squibb. He received grants from Vertex and Janssen. Dr. Habersetzer consults for and advises Gilead. He consults for Transgene and Boehringer Ingelheim. Dr. Zhu is employed by and owns stock in Gilead. Dr. Kanwar is employed by and owns stock in Gilead. Dr. Sulkowski consults for and received grants from Gilead, Merck, AbbVie, Bristol‐Myers Squibb, Boehringer Ingelheim, Janssen, Vertex, and Idenix. He consults for Pfizer. This trial was supported by Gilead Sciences, Inc. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.27053 |
| PMID | 24501005 |
| PQID | 1540468482 |
| PQPubID | 996352 |
| PageCount | 9 |
| ParticipantIDs | unpaywall_primary_10_1002_hep_27053 hal_primary_oai_HAL_hal_02492435v1 proquest_miscellaneous_1542003974 proquest_journals_1540468482 pubmed_primary_24501005 crossref_primary_10_1002_hep_27053 crossref_citationtrail_10_1002_hep_27053 wiley_primary_10_1002_hep_27053_HEP27053 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | July 2014 |
| PublicationDateYYYYMMDD | 2014-07-01 |
| PublicationDate_xml | – month: 07 year: 2014 text: July 2014 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Hepatology (Baltimore, Md.) |
| PublicationTitleAlternate | Hepatology |
| PublicationYear | 2014 |
| Publisher | Wolters Kluwer Health, Inc Wiley-Blackwell |
| Publisher_xml | – name: Wolters Kluwer Health, Inc – name: Wiley-Blackwell |
| References | 2013; 144 2011; 54 2012; 366 2013; 11 2011; 141 2012; 57 2013; 13 2012; 56 2010; 52 2010; 30 2011; 364 2013; 368 Lawitz (10.1002/hep.27053-BIB0007|hep27053-cit-0007) 2012; 57 Chen (10.1002/hep.27053-BIB0011|hep27053-cit-0011) 2013; 144 Harris (10.1002/hep.27053-BIB0009|hep27053-cit-0009) 2010; 52 Poordad (10.1002/hep.27053-BIB0001|hep27053-cit-0001) 2011; 364 Chen (10.1002/hep.27053-BIB0004|hep27053-cit-0004) 2013; 11 Heim (10.1002/hep.27053-BIB0003|hep27053-cit-0003) 2013; 13 Lawitz (10.1002/hep.27053-BIB0008|hep27053-cit-0008) 2010; 52 Jacobson (10.1002/hep.27053-BIB0002|hep27053-cit-0002) 2011; 364 Butt (10.1002/hep.27053-BIB0014|hep27053-cit-0014) 2010; 30 Lok (10.1002/hep.27053-BIB0005|hep27053-cit-0005) 2012; 366 Poordad (10.1002/hep.27053-BIB0013|hep27053-cit-0013) 2013; 368 Zeuzem (10.1002/hep.27053-BIB0006|hep27053-cit-0006) 2011; 141 Everson (10.1002/hep.27053-BIB0010|hep27053-cit-0010) 2012; 56 Tong (10.1002/hep.27053-BIB0012|hep27053-cit-0012) 2011; 54 |
| References_xml | – volume: 366 start-page: 216 year: 2012 end-page: 224 article-title: Preliminary study of two antiviral agents for hepatitis C genotype 1 publication-title: N Engl J Med – volume: 364 start-page: 1195 year: 2011 end-page: 1206 article-title: Boceprevir for untreated chronic HCV genotype 1 infection publication-title: N Engl J Med – volume: 56 start-page: 572A issue: Suppl year: 2012 article-title: The NS5A inhibitor GS‐5885 is safe and well tolerated in more than 1000 patients treated in phase 2 studies [Abstract] publication-title: Hepatology – volume: 54 start-page: S487 issue: Suppl year: 2011 article-title: In vitro studies on the potential for the hepatitis c virus protease inhibitors GS‐9256 and GS‐9451 to affect bilirubin elimination [Abstract] publication-title: J Hepatol – volume: 364 start-page: 2405 year: 2011 end-page: 2416 article-title: Telaprevir for previously untreated chronic hepatitis C virus infection publication-title: N Engl J Med – volume: 13 start-page: 535 year: 2013 end-page: 542 article-title: 25 years of interferon‐based treatment of chronic hepatitis C: an epoch coming to an end publication-title: Nat Rev Immunol – volume: 11 start-page: 1014 year: 2013 end-page: 1020 article-title: A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir publication-title: Clin Gastroenterol Hepatol – volume: 52 start-page: 772A issue: Suppl year: 2010 article-title: Antiviral response and resistance analysis of treatment‐naïve HCV infected subjects receiving single and multiple doses of GS‐9190 [Abstract] publication-title: Hepatology – volume: 368 start-page: 45 year: 2013 end-page: 53 article-title: Exploratory study of oral combination antiviral therapy for hepatitis C publication-title: N Engl J Med – volume: 144 start-page: 1450 year: 2013 end-page: 1455 article-title: Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies publication-title: Gastroenterology – volume: 57 start-page: 24 year: 2012 end-page: 31 article-title: A phase 1, randomized, placebo‐controlled, 3‐day, dose‐ranging study of GS‐5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C publication-title: J Hepatol – volume: 30 start-page: 240 year: 2010 end-page: 250 article-title: Hepatitis C treatment completion rates in routine clinical care publication-title: Liver Int – volume: 52 start-page: 714A issue: Suppl year: 2010 end-page: 715A article-title: Three‐day, dose‐ranging study of the HCV NS3 protease inhibitor GS‐9451 [Abstract] publication-title: Hepatology – volume: 141 start-page: 2047 year: 2011 end-page: 2055 article-title: Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection publication-title: Gastroenterology – volume: 13 start-page: 535 year: 2013 ident: 10.1002/hep.27053-BIB0003|hep27053-cit-0003 article-title: 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end publication-title: Nat Rev Immunol doi: 10.1038/nri3463 – volume: 56 start-page: 572A issue: Suppl year: 2012 ident: 10.1002/hep.27053-BIB0010|hep27053-cit-0010 article-title: The NS5A inhibitor GS-5885 is safe and well tolerated in more than 1000 patients treated in phase 2 studies [Abstract] publication-title: Hepatology – volume: 52 start-page: 714A issue: Suppl year: 2010 ident: 10.1002/hep.27053-BIB0008|hep27053-cit-0008 article-title: Three-day, dose-ranging study of the HCV NS3 protease inhibitor GS-9451 [Abstract] publication-title: Hepatology – volume: 54 start-page: S487 issue: Suppl year: 2011 ident: 10.1002/hep.27053-BIB0012|hep27053-cit-0012 article-title: In vitro studies on the potential for the hepatitis c virus protease inhibitors GS-9256 and GS-9451 to affect bilirubin elimination [Abstract] publication-title: J Hepatol doi: 10.1016/S0168-8278(11)61234-8 – volume: 364 start-page: 2405 year: 2011 ident: 10.1002/hep.27053-BIB0002|hep27053-cit-0002 article-title: Telaprevir for previously untreated chronic hepatitis C virus infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1012912 – volume: 144 start-page: 1450 year: 2013 ident: 10.1002/hep.27053-BIB0011|hep27053-cit-0011 article-title: Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.02.039 – volume: 368 start-page: 45 year: 2013 ident: 10.1002/hep.27053-BIB0013|hep27053-cit-0013 article-title: Exploratory study of oral combination antiviral therapy for hepatitis C publication-title: N Engl J Med doi: 10.1056/NEJMoa1208809 – volume: 30 start-page: 240 year: 2010 ident: 10.1002/hep.27053-BIB0014|hep27053-cit-0014 article-title: Hepatitis C treatment completion rates in routine clinical care publication-title: Liver Int doi: 10.1111/j.1478-3231.2009.02156.x – volume: 141 start-page: 2047 year: 2011 ident: 10.1002/hep.27053-BIB0006|hep27053-cit-0006 article-title: Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection publication-title: Gastroenterology doi: 10.1053/j.gastro.2011.08.051 – volume: 366 start-page: 216 year: 2012 ident: 10.1002/hep.27053-BIB0005|hep27053-cit-0005 article-title: Preliminary study of two antiviral agents for hepatitis C genotype 1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1104430 – volume: 52 start-page: 772A issue: Suppl year: 2010 ident: 10.1002/hep.27053-BIB0009|hep27053-cit-0009 article-title: Antiviral response and resistance analysis of treatment-naïve HCV infected subjects receiving single and multiple doses of GS-9190 [Abstract] publication-title: Hepatology – volume: 57 start-page: 24 year: 2012 ident: 10.1002/hep.27053-BIB0007|hep27053-cit-0007 article-title: A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C publication-title: J Hepatol doi: 10.1016/j.jhep.2011.12.029 – volume: 364 start-page: 1195 year: 2011 ident: 10.1002/hep.27053-BIB0001|hep27053-cit-0001 article-title: Boceprevir for untreated chronic HCV genotype 1 infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1010494 – volume: 11 start-page: 1014 year: 2013 ident: 10.1002/hep.27053-BIB0004|hep27053-cit-0004 article-title: A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2013.03.032 |
| SSID | ssj0009428 |
| Score | 2.3343933 |
| Snippet | This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease... |
| SourceID | unpaywall hal proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 56 |
| SubjectTerms | Administration, Oral Adolescent Adult Aged Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Benzimidazoles - administration & dosage Benzimidazoles - adverse effects Drug Resistance, Viral Drug Therapy, Combination Female Fluorenes - administration & dosage Fluorenes - adverse effects Genotype Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Hepatology Human health and pathology Humans Life Sciences Male Middle Aged Purines - administration & dosage Purines - adverse effects Pyridazines - administration & dosage Pyridazines - adverse effects Quinolines - administration & dosage Quinolines - adverse effects Ribavirin - administration & dosage Ribavirin - adverse effects Treatment Outcome Viral Nonstructural Proteins - antagonists & inhibitors Young Adult |
| SummonAdditionalLinks | – databaseName: Wiley Online Library - Core collection (SURFmarket) dbid: DR2 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFH4qPbAc2JdAQWY59ECmTuIsFqdR1SpCFCFEUQ9Ike2x6YjIM5qZDIITR478E34E_4RfwrOzVGUTQsrBiV8cx362v2c_fwZ4xI2kWiVxmCVGh0wxFRZSpKGIJWMCR5Qod3uHD55n5SF7epQebcCTfi9Myw8xTLi5luH7a9fAhVzunJCGHuv5KM5Rh7D_jZLMm1MvT6ijOPPnqqLVRd3qMu9ZhWi8M7x5aiw6c-w8IX-FmRfgXGPn4sN7UdenEawfgvYvwZs-863nybtRs5Ij9fEnXsf__LvLcLGDpmTc6tIV2ND2Kpw96Bbfr8HncV1___TFbeknmBya1L5WycyQGoXmYrmeLh6TtZ4s3NEq_mal385k44PCTshiKgXeTC3Ba_Bxx0St-PZ1rUnH8rokbnqYOP5YN0VMIlLuvia935i9Dof7e692y7A7yCFUjv8tTBAIsAkvqEKwwJUWNEPDtFARFYKn0mRJrjNd6CJ2bGc5jpgRixCpcKUoBnlyAzbtzOpbQIpE54kxPBUqYlKYIhaI4VIdqSw1VJsAtvsqrVTHcu4O26irlp85rrBkK1-yATwYROcttcdvhVAvhnhHxl2On1XumSdbRLS5jgLY6tWm6rqAZYXYlLKsYEUcwP0hGhuvW5ERVs8aL-OcA9GmC-Bmq27Dp2KWoq1M0wAeDvr3t3xue3X6s0RV7r3wgdv_LnoHziNAZK178hZsrhaNvosgbCXv-db2A-sdLcQ priority: 102 providerName: Wiley-Blackwell |
| Title | All‐oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment‐naïve patients with genotype 1 HCV infection |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.27053 https://www.ncbi.nlm.nih.gov/pubmed/24501005 https://www.proquest.com/docview/1540468482 https://www.proquest.com/docview/1542003974 https://hal.science/hal-02492435 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.27053 |
| UnpaywallVersion | publishedVersion |
| Volume | 60 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1527-3350 dateEnd: 20241101 omitProxy: true ssIdentifier: ssj0009428 issn: 1527-3350 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1527-3350 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1527-3350 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009428 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9QwFH6iU4nlwL4ESmWWQw9kSBw7y3FUtQTUDqNqppRTcDwOMyJKotkQnPk__Aj-GM_OIsomJKQc7ORlsf2e_T375TPA0yhLHSU9avtepmwmmbTDVHBb0JQxgSOKG-h_h4-Hfjxhr874WbPPqf4XpuaH6CbctGWY_lobeDXN6n6-Wd2nz2eq6tMA9WgLtn2OYLwH25PhaPDWzKwEjl5XjgxjKkVT8rjTcgv9eO-5EWlrpuMhfwWbV-DSuqjEp48iz8_jWDMQHV6Dd20R6viTD_31Ku3Lzz-xO_5HGa_D1QakkkGtVTfggipuwsXjZhn-FnwZ5Ln9eoEi2J2ga21al5QZOUKRSiw388UzcqqmC73FismM1fsyXZukKKbkZJ4KzMwLgse4jXW3h-Lb140io5rrdUnezFcz8kIVpZ4oJi6J90_JyyZ6rLgNk8OD8X5sN9s52FKzwNkewgE2jUJHImSIpBKOj-5pKF1HiIinme8FylehCqnmPAtw3HSZi3glktLBZOTdgV5RFuoekNBTgZdlERfSZanIQioQyXHlSp9njsos2GubNJEN17neciNPapZmmmCtJqZWLXjciVY1wcdvhVAvuuuakjseHCX6nKFcRMy5cS3YadUmaTqCZYII1WF-yEJqwaPuMpqwXpcRhSrXRkaHCKJnZ8HdWt26V1HG0WN2uAVPOv3723fuGXX6s0QSH4xM4v4_PfABXEaEyOr45B3orRZr9RBR2CrdRf_jhO429vYdqwYuFg |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB61RaJw4E0JFDCPQw9k6yTOS-KyqloF2K0QalEvVeR4nXZFlF3tbhbBiSNH_gk_gn_CL2HGeVTlJYSUgxNPHMce29_Y488AT-M841p5rh14ubaFEsqOMunb0s2EkDiiOCHtHR7uB8mheHnkH63A83YvTM0P0U24Ucsw_TU1cJqQ3j5jDT3V054bohKtwgURoJ1CkOjNGXlULMzJqmh3cVpfjlteIe5ud6-eG41WT8kX8legeRnWq3IqP7yXRXEew5pBaO8qHLfZr31P3vWqRdZTH39idvzf_7sGVxp0yvq1Ol2HFV3egIvDZv39JnzuF8X3T19oVz_D9NCqNhXLJjkrUGgq58vx7Blb6tGMTlcxNwt9MskqE5TliM3GmcSbccnw6tzcMdFSfvu61Kwhep0zmiFmRCFLs8TMYcnOW9a6jpW34HBv92AnsZuzHGxFFHC2h1hAjOKIK8QLsdKSB2ibRsrhUsZ-lgdeqAMd6cglwrMQB01HOAhWYqU4BmPvNqyVk1LfARZ5OvTyPPalckQm88iVCON87ajAz7nOLdhq6zRVDdE5nbdRpDVFs5tiyaamZC143IlOa3aP3wqhYnTxxMed9AcpPTN8iwg4l44Fm63epE0vME8RnnIRRCJyLXjURWP7pUUZWepJZWTIPxDNOgs2an3rPuUKH81l7lvwpFPAv-Vzy-jTnyXSZPe1Cdz9d9GHsJ4cDAfp4MX-q3twCfGiqL2VN2FtMav0fcRki-yBaXo_ALjUMeU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL1qi1TKgvcjUMA8Fl2QqZM4iSOxGbUdDdBWFaJVNyhyPHY7IspEM5NBsGLJkj_hI_gTvoRr51GVlxBSFk584zj2tX2ufX0M8DTRGVUy8N0o0MplkkmXZyJ0hZ8xJnBE8WKzd3hvPxoespfH4fESPG_3wtT8EN2Em2kZtr82DVyVI715xhp6qsqeH6MSLcMFFibcOPRtvz4jj0qYPVkV7S5q1peTlleI-pvdq-dGo-VT4wv5K9C8BBerohQf3os8P49h7SA0uAJv2-zXvifvetU868mPPzE7_u__XYXLDTol_VqdrsGSKq7D6l6z_n4DPvfz_PunL2ZXP8H00Kq2FUsmmuQoVIrZYjx9RhZqNDWnq9ibuTqZZJUNimJEpuNM4M24IHh1bu6YaCG-fV0o0hC9zoiZISaGQtbMEhOPDLeOSOs6VtyEw8HOm62h25zl4EpDAecGiAXYKOFUIl5IpBI0QtuUS48KkYSZjoJYRYor7hvCsxgHTY95CFYSKSkGk-AWrBSTQt0BwgMVB1onoZAey4TmvkAYFypPRqGmSjuw0dZpKhuic3PeRp7WFM1-iiWb2pJ14HEnWtbsHr8VQsXo4g0f97C_m5pnlm8RAefCc2C91Zu06QVmKcJTyiLOuO_Aoy4a269ZlBGFmlRWxvgHolnnwO1a37pP-SxEc5mGDjzpFPBv-dyw-vRniXS4c2ADd_9d9CGsHmwP0t0X-6_uwRrCRVY7K6_DynxaqfsIyebZA9vyfgAeRDFp |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jj9MwFH5iOhIMB_YlMCCzHOZAipPYWY7VaIaCZkqF2mE4Bcd1phVRErVNEZz5P_wI_hjPziKGTUhIOdjxy2L7Pfuz_fwZ4GmUJlRJz7V9L1U2k0zaYSK4LdyEMYE9ihPovcPHI384Za9O-WlzzqneC1PzQ3QTbtoyTHutDbycpXU736zuu8_nquy7AerRFmz7HMF4D7ano_HgnZlZCaheV44MY6qLpuRx2nIL_fjsuR5pa679IX8Fm5fhUpWX4tNHkWXncazpiA6vwvs2C7X_yYd-tU768vNP7I7_kcdrcKUBqWRQa9V1uKDyG3DxuFmGvwlfBllmv16iCDYnOLQ2tUuKlByhSClWm8XyGTlRs6U-YsVEJuqsSCoTFPmMvFkkAiOLnOA1aX3d7ZH49nWjyLjmel2Rt4v1nLxQeaEniolDhvsn5GXjPZbfgunhwWR_aDfHOdhSs8DZHsIBNotCKhEyRFIJ6uPwNJQOFSLiSep7gfJVqEJXc54F2G86zEG8EklJMRh5t6GXF7m6CyT0VOClacSFdFgi0tAViOS4cqTPU6pSC_baKo1lw3Wuj9zI4pql2Y2xVGNTqhY87kTLmuDjt0KoF126puQeDo5ifc9QLiLm3DgW7LZqEzcNwSpGhEqZH7LQteBRl4wmrNdlRK6KyshoF0Ec2Vlwp1a37lMu4zhiptyCJ53-_e0_94w6_VkiHh6MTeDeP73wPuwgQmS1f_Iu9NbLSj1AFLZOHjaW9h2cXy0t |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=All-oral+combination+of+ledipasvir%2C+vedroprevir%2C+tegobuvir%2C+and+ribavirin+in+treatment-na%C3%AFve+patients+with+genotype+1+HCV+infection&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Wyles%2C+David+L&rft.au=Rodriguez-Torres%2C+Maribel&rft.au=Lawitz%2C+Eric&rft.au=Shiffman%2C+Mitchell+L&rft.date=2014-07-01&rft.pub=Wolters+Kluwer+Health%2C+Inc&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=60&rft.issue=1&rft.spage=56&rft_id=info:doi/10.1002%2Fhep.27053&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=3349667401 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |